AstraZeneca PLC ADR (AZN) - Stock Price & Dividends

Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US0463531089

AstraZeneca PLC, a biopharmaceutical company, is dedicated to developing and distributing prescription drugs. Their products cover a range of areas, from oncology to respiratory and immunology, as well as rare diseases and cardiovascular health. They offer a variety of medications like Lumoxiti, Orpathys, Brilinta, and Farxiga among others, catering to different medical needs.

In addition to their extensive product portfolio, AstraZeneca collaborates with various organizations to advance research and development in fields like hypercholesterolemia and potential therapeutic cell applications. They are also actively involved in developing treatments for conditions such as advanced hepatocellular carcinoma.

Originally known as Zeneca Group PLC, AstraZeneca PLC has been in operation since 1992 and is headquartered in Cambridge, United Kingdom. They serve healthcare providers globally through their network of distributors and local offices, ensuring access to their innovative medications and treatments.

To learn more about AstraZeneca PLC and their initiatives, visit their website

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for AstraZeneca PLC ADR (AZN) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for AstraZeneca PLC ADR (AZN) - Stock Price & Dividends

AZN Stock Overview

Market Cap in USD 209,619m
Sector Healthcare
Industry Drug Manufacturers - General
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 1993-05-12

AZN Stock Ratings

Growth 5y 6.68
Fundamental 4.90
Dividend 6.07
Rel. Performance vs Sector -1.13
Analysts 4.38/5
Fair Price Momentum 67.58 USD
Fair Price DCF 59.24 USD

AZN Dividends

Yield 12m 2.12%
Yield on Cost 5y 4.24%
Dividends CAGR 5y 0.70%
Payout Consistency 96.7%

AZN Growth Ratios

Growth 12m -6.26%
Growth Correlation 12m -37%
Growth Correlation 3m 53%
CAGR 5y 14.83%
Sharpe Ratio 12m -0.53
Alpha vs SP500 12m -21.62
Beta vs SP500 5y weekly 0.57
ValueRay RSI 70.62
Volatility GJR Garch 1y 21.16%
Price / SMA 50 3.75%
Price / SMA 200 3.97%
Current Volume 4005.9k
Average Volume 20d 5298.7k

External Links for AZN Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of AZN stocks?
As of April 19, 2024, the stock is trading at USD 68.36 with a total of 4,005,892 shares traded.
Over the past week, the price has changed by -1.57%, over one month by +3.81%, over three months by +4.35% and over the past year by -6.87%.
What is the forecast for AZN stock price target?
According to ValueRays Forecast Model, AZN AstraZeneca PLC ADR will be worth about 74.2 in April 2025. The stock is currently trading at 68.36. This means that the stock has a potential upside of +8.54%.
Issuer Forecast Upside
Wallstreet Target Price 81.8 19.7%
Analysts Target Price 83.7 22.5%
ValueRay Target Price 74.2 8.54%

AstraZeneca PLC ADR: Its Journey, Core, and Market Standing

History of AstraZeneca

AstraZeneca, a global name in the pharmaceutical and biopharmaceutical industry, was founded through the merger of Astra AB and Zeneca Group PLC in 1999. Astra AB of Sweden and Zeneca Group of the United Kingdom, both having rich histories in healthcare and chemicals, combined their strengths to form a powerhouse. This merger was not just a fusion of two companies but a strategic move to enhance research capabilities, expand product portfolios, and improve global presence in the competitive pharmaceutical market.

Core and Side Businesses

The core business of AstraZeneca revolves around the discovery, development, and commercialization of prescription medicines. The company operates primarily in three main therapeutic areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory. AstraZeneca's efforts in these areas have led to the development of breakthrough therapies and treatments that have significantly impacted patients' lives worldwide.

Beyond its pharmaceutical ventures, AstraZeneca also invests in biotech startup companies through its venture fund arm. This not only helps the company stay at the forefront of biotechnological advancements but also diversifies its business interests and revenue streams.

Current Market Status

As of the latest update, AstraZeneca PLC ADR (NASDAQ:AZN) continues to be a prominent player in the pharmaceutical industry, with a robust presence in markets across the globe. The company's strategic collaborations, innovative drug pipeline, and a strong focus on research and development have positioned it well for sustainable growth. Investors and market analysts often highlight AstraZeneca's growth potential, especially in emerging markets and through its next-generation therapies.

The COVID-19 pandemic brought significant attention to AstraZeneca due to its development of a vaccine in collaboration with Oxford University. This not only showcased the company's rapid response capabilities in public health emergencies but also its commitment to addressing global health challenges.

In the ever-evolving world of healthcare and pharmaceuticals, AstraZeneca remains a key figure, pushing forward with its mission to deliver life-changing medicines and contribute to the betterment of global health.